Form 4: CalciMedica Insider Reports Stock Option Activity

Michael J. Dunn, President and COO of CalciMedica, Inc., reported a transaction involving employee stock options.

Summary

• Michael J. Dunn, President and COO of CalciMedica, Inc., filed a Form 4 statement detailing a transaction related to employee stock options.
• The transaction involves 65,124 shares subject to an employee stock option with an exercise price of $0.585.
• Vesting of these options is scheduled to begin on April 1, 2026, with 1/48th of the shares vesting monthly over four years.
• However, vesting is contingent upon the company filing a Form S-8 registration statement for the shares under its 2023 Equity Incentive Plan.
• The shares were automatically added to the authorized issuance under the plan on January 1, 2026, due to an annual 'evergreen' provision.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports standard insider stock option activity with a conditional vesting schedule that introduces a degree of uncertainty.

Positives

• The filing indicates ongoing equity incentive plans for key personnel, suggesting a commitment to employee retention and motivation.
• The structure of the stock option, with a future vesting start date, aligns with long-term performance expectations.

Negatives

• Vesting is explicitly tied to the filing of a Form S-8, which introduces a potential delay or conditionality to the employee's benefit.
• The specific date for the Form S-8 filing is not provided, creating uncertainty regarding the actual commencement of vesting.

Risks

• The primary risk is the delay or failure to file the Form S-8 registration statement, which would prevent the stock options from vesting.
• Market conditions or company performance could impact the value of the stock options by the time they vest.

Future Outlook

The future outlook for the stock options is contingent on the company filing a Form S-8 registration statement, after which vesting is expected to occur in monthly installments over four years starting April 1, 2026.

Management Comments

• "Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual 'evergreen' provision."

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions, including the grant or exercise of stock options. The conditional vesting tied to an S-8 filing is a common mechanism to ensure compliance with securities regulations before shares can be formally registered for employee benefit plans.

Corporate Governance

Stakeholder Impact

• Shareholders: The conditional nature of the stock option vesting may have minor implications for future dilution, depending on the timing of the S-8 filing and subsequent vesting.
• Employees: Key employees, including Michael J. Dunn, are subject to a vesting schedule that is dependent on regulatory filings, impacting their potential compensation.
• Management: The filing details compensation-related equity awards for a key executive, reflecting standard practice in executive compensation.

Next Steps

• CalciMedica, Inc. must file a Form S-8 registration statement to enable the vesting of the reported stock options.
• Michael J. Dunn's stock options will begin vesting monthly over four years after the Form S-8 is filed, starting no earlier than April 1, 2026.

Key Dates

Keywords

Form 4, SEC Filing, CalciMedica, CALC, Stock Options, Employee Stock Option, Equity Incentive Plan, Vesting Schedule, Michael J. Dunn, President and COO, Form S-8